My hopefull support group message!
Funny. I crisscross the country, flying here and there, speaking to myeloma support groups from coast to coast. Yet I rarely address our local group here north of Tampa. Last night I was the...
View ArticleCould ectoenzyme CD38 hold the key to a myeloma cure?
A surprising source of myeloma related information can be found on business/investment websites. I have written about this before. With big bucks at stake, financial newsletters and investment firms...
View ArticleUpdated 2013 edition, New Multiple Myeloma Therapies from a Patient’s...
My updated 2013 edition of New Multiple Myeloma Therapies from a Patient’s Perspective has just been published. When I wrote the book less than a year ago, I knew things were changing quickly in...
View ArticleDaratumumab ready for Stage 2 testing
Always nice to report on a promising development. Check-out this press release about the new rising myeloma therapy star, daratumumab, that I received last week: Genmab Announces New Study of...
View ArticleCost and lack of access to myeloma care hurting patients
This is an example of a more general topic that I might post on our HelpWithCancer.org site. But I felt this article, on NBC News.com, was something my readers here should see. Here’s an excerpt....
View ArticleNew pathway may hold key to multiple myeloma cure
Could immunotherapy be the key to a multiple myeloma cure? One thing’s for sure; new drugs like elotuzumab and daratumumab offer hope that researchers are developing new and significant ways to attack...
View ArticleFDA approval of new CLL antibody bodes well for myeloma patients
Great news for our fellow blood cancer patients with chronic lymphocytic leukemia (CLL)! And I think it’s good news for myeloma patients, too. An antibody created by scientists has been FDA approved...
View ArticleNew daratumumab/Revlimid study recruiting now!
There was good news on the drug development front this week. Most myeloma experts agree that the experimental immunotherapy drug, daratumumab, is the most promising anti-myeloma drug in it’s class so...
View ArticleProof clarithromycin can help overcome myeloma drug resistance
From what may be possible in the future to an easy way to temporarily overcome myeloma drug resistance now. Apparently adding something as simple and innocuous as an antibiotic can add four or more...
View ArticleNew daratumumab study recruiting now
Genmab, the makers of the experimental immunotherapy, daratumumab, announced plans to launch a new Phase 3 study for relapsed/refractory patients last week: Genmab Announces New Phase III Study of...
View ArticleExpect new myeloma research data in June
There are a pair of important medical meetings just around the corner that should give us an idea about how well several of the new myeloma therapies are working in real live patients. The American...
View ArticleNew Phase 3 daratumumab clinical trial to start recruiting soon
Following Friday’s post about the release of important clinical trial data at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) meetings in June, Joe asked...
View ArticleMMRF excited about new myeloma therapy, SAR650984
Walter Capone, President of the Multiple Myeloma Research Foundation (MMRF), is excited about a new myeloma therapy: SAR650984. He mentioned this exciting new therapeutic option for heavily pretreated...
View ArticleASCO News: panobinostat, SAR650984 and daratumumab
I’ll spend the next few days sharing and interpreting data from the American Society of Clinical Oncology (ASCO) annual meetings at McCormick Place on Chicago’s waterfront. But why reinvent the wheel?...
View ArticleNew daratumumab study enrolling newly diagnosed, older patients
Janssen Biotech recently announced that it’s enrolling newly diagnosed multiple myeloma patients that aren’t eligible for a stem cell transplant. The majority of ineligible transplant patients are...
View ArticleHopeful immunotherapy update from ASH
As promised, here’s an update on the two hottest immunotherapies at ASH this year: daratumumab and SAR650984. Here are excerpts from Silas Inman’s article, Anti-CD38 Antibodies Highly Effective in...
View ArticleDr. Noopur Raje reviews immunotherapy data from ASH
I had the good fortune of dining with Dr. Noopur Raje last evening here in San Francisco. We discussed several of the studies she reviews in this CancerNetwork.com article: New Developments in...
View ArticleIf this works out a lot of us may live longer…
Our next, best shot: immunotherapy agents that attack CD38 proteins on the cell walls of multiple myeloma cells: Anti-CD38 antibodies poised to transform myeloma treatment By: PATRICE WENDLING,...
View ArticleMyeloma therapy advances big and small
Speaking of new treatment options, here’s an excerpt from an excellent summary of what I consider to be “stopgap” myeloma therapy measures until new immunotherapy technology moves front and center:...
View ArticleSub-q daratumumab study announced
Following Takeda’s lead with sub-q Velcade, Genmab hopes that their new immunotherapy, daratumumab, will work sub-q, too. I like it! These guys aren’t wasting any time. Daratumumab isn’t even FDA...
View Article
